TESA · 20 mg / vial
Tesamorelin
$254 AUD
In stockStabilized analog of growth hormone-releasing hormone (GHRH).
- Purity
- ≥ 99.3%
- Dose
- 20 mg / vial
- Form
- Lyophilized
- QC
- HPLC + MS
What it does
Tesamorelin is a stabilized 44-amino-acid analog of growth hormone-releasing hormone (GHRH). Rather than replacing growth hormone directly, it acts upstream on the pituitary to restore the body's own natural, pulsatile release of GH and downstream IGF-1. This preserves the physiological rhythm of GH secretion, which is why it is the only GHRH analog approved for the reduction of HIV-associated visceral adipose tissue.
How it works in the body
It taps your brain on the shoulder and says 'hey, release growth hormone like you did when you were younger' — mostly while you sleep. That natural nightly pulse helps burn off deep belly fat, hold onto muscle, and improves recovery. It works with your body's normal rhythm instead of overriding it.
Researched benefits
- Targeted reduction of visceral (deep abdominal) adipose tissue
- Improved triglycerides, cholesterol ratios and adiponectin levels
- Preserved or modest gains in lean muscle mass
- Better sleep depth and recovery via restored nocturnal GH pulse
- Improved skin elasticity and connective-tissue repair signalling
Typical research protocol
- Reconstitution
- Add 2 mL bacteriostatic water to the 20 mg vial → 10 mg/mL (1 pen unit = 0.1 mg / 100 mcg).
- Dose
- Typical research dose: 1 mg (1,000 mcg) per day, with some protocols going up to 2 mg (2,000 mcg).
- Pen units (U-100)
- At 10 mg/mL: 1 mg = 10 units, 2 mg = 20 units on a U-100 peptide pen.
- Frequency
- Once daily, preferably at night before bed on an empty stomach.
Recommended: use a single-use, sterile drawing syringe and needle for reconstitution — available in the accessories section.
For in-vitro research only — not for human or veterinary consumption.
Potential side effects
- Injection-site redness, itching, swelling or lipohypertrophy
- Joint pain, muscle aches and peripheral fluid retention
- Numbness or tingling in the hands (carpal-tunnel-type symptoms)
- Reduced insulin sensitivity / raised fasting glucose with prolonged use
- Headache and vivid dreams when dosed pre-bed
Reported in published literature and research reports. Not exhaustive and not medical advice — this product is supplied for laboratory research only.
Deep dive · properties
The nerdy details 🔬
- Half-life
- ~26 minutes (short pulse, physiological)
- Sequence / class
- Stabilized 44-residue GHRH analog (trans-3-hexenoyl modification)
- Molecular weight
- ≈ 5,196 Da
- Origin
- FDA-approved 2010 for HIV-associated lipodystrophy (Egrifta®)
- Storage & stability
- Store lyophilized vials at –20 °C for long-term storage (up to 24 months). Once reconstituted, refrigerate at 2–8 °C and use within 28 days. Protect from light and freeze/thaw cycles.
Common questions
Wait, quick question. 🙋
Why dose at night?
Endogenous GH release is naturally pulsatile and peaks during deep sleep. Dosing tesamorelin before bed on an empty stomach amplifies that nocturnal pulse rather than fighting it.
Do I need to stack it with a GHRP like ipamorelin?
Not required — tesamorelin works standalone. Some research protocols pair a GHRH analog with a GHRP for synergistic pituitary release, but that is an addition, not a requirement.
Published research
Where the data lives 📚
- Falutz J, et al. Effects of tesamorelin on visceral fat in HIV lipodystrophy ↗
NEJM, 2007
- Stanley TL, et al. Effect of tesamorelin on visceral adipose tissue in HIV ↗
JAMA, 2014
Linked purely for research context. Sold for laboratory use only.
Tesamorelin
$254 AUD · 20 mg / vial
Research use only · Not for human or veterinary consumption